- Home
- ODD vs PCVX Comparison
ODD vs PCVX Comparison
Compare ODD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | PCVX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 6.0B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODD | PCVX |
|---|---|---|
| Price | $45.33 | $46.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $70.18 | ★ $101.67 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $780,758,000.00 | N/A |
| Revenue This Year | $26.16 | N/A |
| Revenue Next Year | $20.37 | N/A |
| P/E Ratio | $25.28 | ★ N/A |
| Revenue Growth | ★ 25.80 | N/A |
| 52 Week Low | $35.30 | $27.66 |
| 52 Week High | $79.18 | $94.60 |
Technical Indicators
Market Signals| Indicator | ODD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 56.84 | 51.97 |
| Support Level | $41.36 | $43.78 |
| Resistance Level | $44.37 | $48.11 |
| Average True Range (ATR) | 2.34 | 1.99 |
| MACD | 1.18 | -0.49 |
| Stochastic Oscillator | 89.52 | 42.99 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.